Regenlab USA Inc. has taken a significant step towards its initial public offering (IPO) by filing an amended registration statement with the U.S. Securities and Exchange Commission (SEC) on October 27, 2026. This filing, identified by accession number 0001829126-26-011539, includes details about a forward stock split aimed at increasing the number of shares available to potential investors.

The company, which specializes in pharmaceutical preparations, is preparing to offer 2,500,000 shares of its common stock. The anticipated price range for the shares is between $6.00 and $8.00, with the midpoint set at $7.00. This pricing strategy reflects Regenlab's efforts to attract a broader investor base as it transitions into a public company.

Background

Regenlab USA Inc. is incorporated in Delaware and operates within the pharmaceutical preparations sector, classified under SIC Code 2834. The company has been actively preparing for its public debut, with its most recent filings indicating a strong commitment to ensuring a successful market entry. The company’s common stock is expected to be listed on the Nasdaq Stock Market under the ticker symbol RGNA.

What the Filing Says

The amended registration statement outlines a crucial aspect of the IPO: a 3.2-for-1 forward stock split. This means that for every share currently held, shareholders will receive 3.2 shares post-split. The filing states, "Each issued and outstanding share of common stock immediately prior to the effective time of the Forward Stock Split will be converted into 3.2 shares of common stock." This strategy is designed to enhance liquidity and make the shares more accessible to a wider range of investors.

Impact

The forward stock split and the upcoming IPO are likely to impact various stakeholders, including existing shareholders and potential investors. By increasing the number of shares available, Regenlab aims to create a more attractive investment opportunity. Additionally, the company’s principal stockholder, Antonino Turzi, currently controls approximately 98.64% of the voting power of the capital stock and will see this percentage decrease to about 87.66% post-offering.

What's Next

The filing does not specify what happens next, but it indicates that the company will proceed with the IPO as soon as practicable after the effective date of the registration statement. Investors and market analysts will be closely monitoring Regenlab's progress as it approaches this significant milestone.